Imugene Ltd has released a press release.
First Australian Patient Dosed in Phase 1b azer-cel Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Issuance of Convertible Notes & Warrants for up to $46m
- Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
- onCARlytics Trial Doses First Patient in IT Combination Arm
- Imugene Opens First Australian Site for azer-cel Trial
- Complete Response in MAST Study Maintained Over Two Years
Later from Imugene
- Imugene Receives $11.7m R&D Tax Refund
- Imugene Receives A$20 million for Convertible Notes Issuance
- Azer-cel demonstrates two additional Complete Responses
- Imugene OnCARlytics Patent Allowance in China
- Imugene Granted India Patent for Oncolytic Virotherapy CF33
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene